• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

    61.80 -0.93 (-1.48%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,341,772
    Open 62.73
    Bid (Size) 61.70 (200)
    Ask (Size) 63.20 (100)
    Prev. Close 62.73
    Today's Range 60.55 - 63.26
    52wk Range 21.72 - 69.48
    Shares Outstanding 160,500,999
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
    The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
    Via MarketMinute
    Topics Artificial Intelligence Intellectual Property

    Performance

    YTD
    +119.1%
    +119.1%
    1 Month
    +11.8%
    +11.8%
    3 Month
    +32.7%
    +32.7%
    6 Month
    +80.9%
    +80.9%
    1 Year
    +138.8%
    +138.8%

    More News

    Read More
    BridgeBio to Participate in November Investor Conferences
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    Earnings Scheduled For October 29, 2025
    Via Benzinga
    Earnings Outlook For BridgeBio Pharma
    Via Benzinga
    BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings.
    Via Investor's Business Daily
    BridgeBio Pharma (NASDAQ:BBIO) Q3 2025 Revenue Beat Overshadowed by Widened Loss
    Via Chartmill
    BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio's Investigation Drug Outperforms Standard Therapy In Rare Calcium Disorder
    Via Benzinga
    BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results
    Via Stocktwits
    BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High
    Via Investor's Business Daily
    BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial
    Via Stocktwits
    BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition
    Via Benzinga
    BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival
    Via Investor's Business Daily
    Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Inc (NASDAQ:BBIO) Shows Strong Technical Setup for Potential Breakout
    Via Chartmill
    BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is BridgeBio Pharma, Inc. - Common Stock publicly traded?
    Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.
    What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?
    BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?
    The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market
    What is the current price of BridgeBio Pharma, Inc. - Common Stock?
    The current price of BridgeBio Pharma, Inc. - Common Stock is 61.80
    When was BridgeBio Pharma, Inc. - Common Stock last traded?
    The last trade of BridgeBio Pharma, Inc. - Common Stock was at 11/07/25 04:00 PM ET
    What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?
    The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 9.92B
    How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?
    BridgeBio Pharma, Inc. - Common Stock has 10B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.